Pharma tech innovation: Voices from the builders and their backers

For more than a decade, we’ve believed that pharma tech is one of the most compelling opportunities in healthcare. Massive, highly specialized workflows and persistent inefficiencies have created fertile ground for technology-enabled companies to deliver meaningful value, and lately, we’ve noticed we’re no longer alone in that view.

We’ve started to see greater interest in the sector among our peers, and we hear from entrepreneurs that pharma is increasingly willing to engage, experiment, and adopt new technologies. But how much has really changed?

• Are investors more bullish, and where do they want to place their bets?
• Are entrepreneurs finding it easier to sell in today’s environment, and why?
• How are pricing models and value propositions evolving across pharma functions?
• Are investors and entrepreneurs aligned in their perspectives?

To find out, we surveyed more than 100 leading healthcare investors and entrepreneurs building for pharma research, clinical development, and commercial teams. Download the report to explore where investors are placing their bets, how sales dynamics and ROI expectations differ across pharma functions, and what it will take for the next generation of pharma tech companies to win.

If you have additional questions/comments, please contact info@mckessonventures.com.